Merck & Co., Inc. (MRK) 2022 5th Annual Evercore ISI HealthCONx Conference (Transcript)

Dec. 01, 2022 4:24 PM ETMerck & Co., Inc. (MRK)
SA Transcripts profile picture
SA Transcripts
134.01K Followers

Merck & Co., Inc. (NYSE:MRK) 2022 5th Annual Evercore ISI HealthCONx Conference Call December 1, 2022 9:40 AM ET

Company Participants

Peter Dannenbaum - Vice President of Investor Relations

Eliav Barr - Chief Medical Officer & Head of Global Clinical Development of Merck Research Laboratories

Conference Call Participants

Umer Raffat - Evercore ISI

Umer Raffat

Hello, everyone. Thank you for joining us. Pleasure to have Merck management join us. There's tons to talk about. So I'll be talking at 1.5x speed but let me turn it over to you guys to kick things off.

Peter Dannenbaum

Umer, thank you very much for having us. Always a pleasure. With me is Dr. Eliav Barr, who is -- this year he has begun to lead our Global Clinical Development at Merck. He's got a long and distinguished career here, most recently Head of Medical Affairs but also leadership roles in oncology and infectious diseases. And with a cardiologist by training and I just learned that's why he came to Merck back in the mid-'90s was because of the amazing cardiovascular work we were doing then. But happy to turn it over to you, right, to get to your questions.

Question-and-Answer Session

Q - Umer Raffat

Outstanding. So let me kick things off today with a topic on Merck I never get questions on but I think it’s highly relevant. And it’s highly relevant less because of what this new modality is but more so because of what it could mean to KEYTRUDA. So I’m referring specifically to TIGIT. And my question is this. There’s a trial you’re running -- so there are several trials you’re running. They mostly report out in ‘24-‘25 time frame but there’s also this Phase IIb which could come out sort of summer next year. Could that be a registrational trial to form the basis of a fixed-dose

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.